Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus azathioprine for maintenance therapy in relapsing ANCA-associated vasculitis
2012-001102-14Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) comparing Rituximab maintenance with Azathioprine maintenance (2 arms). Primary endpoint: Time to disease relapse. Started Sep 2012; status: completed.
02
Drugs
rituximabazathioprine
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on 2012-001102-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001102-14.